John Alexander Kelly's most recent trade in Precision Biosciences Inc was a trade of 14,827 Common Stock done at an average price of $4.3 . Disclosure was reported to the exchange on July 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.26 per share. | 03 Jul 2025 | 14,827 | 73,485 (0%) | 0% | 4.3 | 63,163 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 82,750 | 82,750 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 1,702 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 1,702 | 86,256 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 44,368 | 84,554 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 26,575 | 53,150 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 13,904 | 27,801 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2025 | 3,889 | 3,888 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Kelly Alexander | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.75 per share. | 27 Dec 2024 | 2,113 | 40,186 (0%) | 0% | 4.8 | 10,037 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.76 per share. | 21 Nov 2024 | 3,000 | 38,073 (0%) | 0% | 6.8 | 20,280 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 3,605 | 3,605 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2024 | 3,605 | 35,073 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2024 | 79,725 | 79,725 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 454 | 31,468 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 454 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.00 per share. | 08 May 2024 | 8,334 | 31,014 (0%) | 0% | 12 | 100,008 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2024 | 41,705 | 41,705 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,702 | 1,702 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,702 | 22,680 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 18.50 per share. | 29 Feb 2024 | 506 | 20,978 (0%) | 0% | 18.5 | 9,361 | Common Stock |
| Precision Biosciences Inc | Kelly John Alexander | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 116,690 | 233,310 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Kelly John Alexander | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2024 | 116,690 | 614,169 (1%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.48 per share. | 18 Aug 2023 | 90,000 | 383,340 (0%) | 0% | 0.5 | 43,200 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 34,091 | 0 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 34,091 | 279,705 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 13,635 | 293,340 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 13,635 | 13,635 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.86 per share. | 17 Mar 2023 | 20,000 | 245,614 (0%) | 0% | 0.9 | 17,200 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 51,071 | 225,614 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 51,071 | 102,114 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.95 per share. | 28 Feb 2023 | 11,605 | 174,543 (0%) | 0% | 1.0 | 11,025 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 350,000 | 350,000 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | Alexander John Kelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2022 | 324,500 | 324,500 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.34 per share. | 22 Sep 2022 | 37,037 | 154,738 (0%) | 0% | 1.3 | 49,630 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.23 per share. | 22 Sep 2022 | 8,200 | 162,938 (0%) | 0% | 1.2 | 10,086 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 22 Jun 2022 | 33,784 | 117,701 (0%) | 0% | 1.5 | 50,676 | Common Stock |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 34,090 | 34,091 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 34,090 | 70,279 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 13,638 | 83,917 (0%) | 0% | - | Common Stock | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 13,638 | 27,270 | - | - | Restricted Stock Units | |
| Precision Biosciences Inc | John Alexander Kelly | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.08 per share. | 17 Mar 2022 | 16,677 | 36,189 (0%) | 0% | 3.1 | 51,365 | Common Stock |